Lumexa Imaging (NASDAQ:LMRI) Updates FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.710-0.770 for the period, compared to the consensus estimate of 0.650. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Lumexa Imaging Stock Up 3.2%

NASDAQ:LMRI traded up $0.25 on Friday, reaching $7.95. 17,509 shares of the company’s stock were exchanged, compared to its average volume of 875,287. The company has a fifty day moving average of $9.24. Lumexa Imaging has a 52 week low of $6.45 and a 52 week high of $19.45.

Wall Street Analysts Forecast Growth

LMRI has been the topic of several recent analyst reports. Weiss Ratings began coverage on shares of Lumexa Imaging in a research note on Wednesday, May 13th. They issued a “sell (e-)” rating on the stock. Barclays cut their price target on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a research note on Wednesday, May 20th. Finally, Raymond James Financial upgraded shares of Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 target price for the company in a research report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Lumexa Imaging presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Insider Activity at Lumexa Imaging

In other Lumexa Imaging news, Director Brett Brodnax purchased 35,000 shares of Lumexa Imaging stock in a transaction that occurred on Tuesday, May 19th. The shares were bought at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the acquisition, the director directly owned 62,027 shares in the company, valued at approximately $449,695.75. This trade represents a 129.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Lumexa Imaging

Hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. bought a new position in shares of Lumexa Imaging during the fourth quarter valued at $37,139,000. Janus Henderson Group PLC bought a new stake in shares of Lumexa Imaging during the fourth quarter valued at approximately $36,860,000. ArrowMark Colorado Holdings LLC bought a new position in Lumexa Imaging in the 4th quarter valued at approximately $27,750,000. Invesco Ltd. purchased a new stake in Lumexa Imaging during the 4th quarter valued at $26,562,000. Finally, Millennium Management LLC purchased a new stake in Lumexa Imaging during the 4th quarter valued at $23,877,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).